News and Announcements
Suda Pharmaceuticals LTD (ASX: SUD) Anagrelide Project benefits from the expansion of its Scientific Advisory Board
- Published September 07, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Professor Stephen Watson joins the Anagrelide Project Scientific Advisory Board, bringing his wealth of expertise and knowledge in platelet function in health and disease and prevention and treatment of cancer and cardiovascular disease to the project.
- The Anagrelide Project represents a radically new, ‘first in class’ approach to cancer treatment.
- With the global cancer market forecast at $111.9 billion by 2020, the Anagrelide Project holds the key to potential utilisation across a broad spectrum of solid tumours.
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, has recently announced the expansion of its Scientific Advisory Board (SAB) for its Anagrelide Project, with the addition of Professor Stephen Watson to the Board.
The Anagrelide Project represents a radical new approach to the treatment of a wide range of cancers, including solid tumors.
A newly constituted anagrelide has the potential to be utilised across a wide range of solid tumors with the common dependency on excess platelets that drive cancer establishment, growth and metastasis.
The drug will be used in conjunction with treatments rendering circulating cancer cells more susceptible to attack by
the body’s own ‘killer cells’.
This treatment presents large, untapped potential with the cancer market tipped at $11.9 billion by 2020.
The SAB provides guidance, support and assessments on the development and progress of the Anagrelide Project.
Professor Watson is A British Heart Foundation Professor, is Head of the Birmingham Platelet Group and is the Co-Director of The Centre of Membrane Proteins and Receptors.
Professor Watson joins current Board members, Dr Richard Franklin and Assoc Professor Nailin Li PhD, MD.
About SUDA Pharmaceuticals Ltd
SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
